Logo image of SPRO

SPERO THERAPEUTICS INC (SPRO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SPRO - US84833T1034 - Common Stock

2.33 USD
-0.01 (-0.43%)
Last: 11/26/2025, 8:04:18 PM
2.31 USD
-0.02 (-0.86%)
After Hours: 11/26/2025, 8:04:18 PM
Fundamental Rating

3

Overall SPRO gets a fundamental rating of 3 out of 10. We evaluated SPRO against 533 industry peers in the Biotechnology industry. SPRO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SPRO has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SPRO has reported negative net income.
SPRO had a negative operating cash flow in the past year.
In the past 5 years SPRO reported 4 times negative net income.
SPRO had a negative operating cash flow in each of the past 5 years.
SPRO Yearly Net Income VS EBIT VS OCF VS FCFSPRO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M -80M

1.2 Ratios

With a Return On Assets value of -86.29%, SPRO is not doing good in the industry: 70.73% of the companies in the same industry are doing better.
SPRO has a Return On Equity of -163.28%. This is in the lower half of the industry: SPRO underperforms 64.35% of its industry peers.
Industry RankSector Rank
ROA -86.29%
ROE -163.28%
ROIC N/A
ROA(3y)-28.91%
ROA(5y)-38.11%
ROE(3y)-62.83%
ROE(5y)-69.97%
ROIC(3y)N/A
ROIC(5y)N/A
SPRO Yearly ROA, ROE, ROICSPRO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SPRO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SPRO Yearly Profit, Operating, Gross MarginsSPRO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

6

2. Health

2.1 Basic Checks

SPRO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SPRO has more shares outstanding
SPRO has more shares outstanding than it did 5 years ago.
There is no outstanding debt for SPRO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SPRO Yearly Shares OutstandingSPRO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
SPRO Yearly Total Debt VS Total AssetsSPRO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -9.38, we must say that SPRO is in the distress zone and has some risk of bankruptcy.
SPRO has a worse Altman-Z score (-9.38) than 70.92% of its industry peers.
There is no outstanding debt for SPRO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.38
ROIC/WACCN/A
WACC8.64%
SPRO Yearly LT Debt VS Equity VS FCFSPRO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 3.97 indicates that SPRO has no problem at all paying its short term obligations.
SPRO has a Current ratio (3.97) which is comparable to the rest of the industry.
A Quick Ratio of 3.97 indicates that SPRO has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.97, SPRO is in line with its industry, outperforming 49.34% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.97
Quick Ratio 3.97
SPRO Yearly Current Assets VS Current LiabilitesSPRO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

SPRO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1228.57%.
SPRO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -53.77%.
SPRO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.46% yearly.
EPS 1Y (TTM)-1228.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.38%
Revenue 1Y (TTM)-53.77%
Revenue growth 3Y37.99%
Revenue growth 5Y21.46%
Sales Q2Q%-59.6%

3.2 Future

The Earnings Per Share is expected to grow by 20.25% on average over the next years. This is a very strong growth
Based on estimates for the next years, SPRO will show a small growth in Revenue. The Revenue will grow by 7.33% on average per year.
EPS Next Y33.34%
EPS Next 2Y59.69%
EPS Next 3Y6.41%
EPS Next 5Y20.25%
Revenue Next Year-48.42%
Revenue Next 2Y-91.23%
Revenue Next 3Y-69.55%
Revenue Next 5Y7.33%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
SPRO Yearly Revenue VS EstimatesSPRO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
SPRO Yearly EPS VS EstimatesSPRO Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SPRO. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 3.33, the valuation of SPRO can be described as very cheap.
99.25% of the companies in the same industry are more expensive than SPRO, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.12, SPRO is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 3.33
SPRO Price Earnings VS Forward Price EarningsSPRO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SPRO Per share dataSPRO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

SPRO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y59.69%
EPS Next 3Y6.41%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SPRO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SPERO THERAPEUTICS INC

NASDAQ:SPRO (11/26/2025, 8:04:18 PM)

After market: 2.31 -0.02 (-0.86%)

2.33

-0.01 (-0.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)03-25 2026-03-25/amc
Inst Owners15.56%
Inst Owner Change1.54%
Ins Owners2.5%
Ins Owner Change1.68%
Market Cap131.13M
Revenue(TTM)47.98M
Net Income(TTM)-53.60M
Analysts45.71
Price Target5.1 (118.88%)
Short Float %1.12%
Short Ratio0.67
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)73.85%
Min EPS beat(2)55.44%
Max EPS beat(2)92.26%
EPS beat(4)3
Avg EPS beat(4)35.29%
Min EPS beat(4)-20.18%
Max EPS beat(4)92.26%
EPS beat(8)6
Avg EPS beat(8)123.11%
EPS beat(12)9
Avg EPS beat(12)181.96%
EPS beat(16)10
Avg EPS beat(16)134.75%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 3.33
P/S 2.7
P/FCF N/A
P/OCF N/A
P/B 3.99
P/tB 3.99
EV/EBITDA N/A
EPS(TTM)-0.79
EYN/A
EPS(NY)0.7
Fwd EY29.99%
FCF(TTM)-0.57
FCFYN/A
OCF(TTM)-0.57
OCFYN/A
SpS0.86
BVpS0.58
TBVpS0.58
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -86.29%
ROE -163.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-28.91%
ROA(5y)-38.11%
ROE(3y)-62.83%
ROE(5y)-69.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.78
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.97
Quick Ratio 3.97
Altman-Z -9.38
F-Score3
WACC8.64%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1228.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.38%
EPS Next Y33.34%
EPS Next 2Y59.69%
EPS Next 3Y6.41%
EPS Next 5Y20.25%
Revenue 1Y (TTM)-53.77%
Revenue growth 3Y37.99%
Revenue growth 5Y21.46%
Sales Q2Q%-59.6%
Revenue Next Year-48.42%
Revenue Next 2Y-91.23%
Revenue Next 3Y-69.55%
Revenue Next 5Y7.33%
EBIT growth 1Y-370.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-366.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-366.99%
OCF growth 3YN/A
OCF growth 5YN/A

SPERO THERAPEUTICS INC / SPRO FAQ

What is the ChartMill fundamental rating of SPERO THERAPEUTICS INC (SPRO) stock?

ChartMill assigns a fundamental rating of 3 / 10 to SPRO.


What is the valuation status of SPERO THERAPEUTICS INC (SPRO) stock?

ChartMill assigns a valuation rating of 4 / 10 to SPERO THERAPEUTICS INC (SPRO). This can be considered as Fairly Valued.


What is the profitability of SPRO stock?

SPERO THERAPEUTICS INC (SPRO) has a profitability rating of 0 / 10.


What is the earnings growth outlook for SPERO THERAPEUTICS INC?

The Earnings per Share (EPS) of SPERO THERAPEUTICS INC (SPRO) is expected to grow by 33.34% in the next year.